Longitudinal Alzheimer's Disease Progression Prediction With Modality Uncertainty and Optimization of Information Flow
Alzheimer's disease (AD) is a global neurodegenerative disorder that affects millions of individuals worldwide. Actual AD imaging datasets challenge the construction of reliable longitudinal models owing to imaging modality uncertainty. In addition, they are still unable to retain or obtain important information during disease progression from previous to followup time points. For example, the output values of current gates in recurrent models should be close to a specific value that indicates the model is uncertain about retaining or forgetting information. In this study, we propose a model which can extract and constrain each modality into a common representation space to capture intermodality interactions among different modalities associated with modality uncertainty to predict AD progression. In addition, we provide an auxiliary function to enhance the ability of recurrent gate robustly and effectively in controlling the flow of information over time using longitudinal data. We conducted comparative analysis on data from the Alzheimer's Disease Neuroimaging Initiative database. Our model outperformed other methods across all evaluation metrics. Therefore, the proposed model provides a promising solution for addressing modality uncertainty challenges in multimodal longitudinal AD progression prediction.
Authors
- Duy-Phuong Dao (ORCID: https://orcid.org/0000-0002-0780-2335)
- Jahae Kim (ORCID: https://orcid.org/0000-0003-4077-7722)
- Ngoc-Huynh Ho (ORCID: https://orcid.org/0000-0002-7539-2016)
- Hyung-Jeong Yang (ORCID: https://orcid.org/0000-0003-3024-5060)
Institutions
- Chonnam National University (KR)
Publication Details
- Journal
- IEEE Journal of Biomedical and Health Informatics
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1109/jbhi.2024.3472462
- Citations
- 14
- Primary Topic
- Artificial Intelligence in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 9.91
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Mike and Josie Harper Cancer Research Institute
- National Research Foundation
- Chonnam National University
- National Research Foundation of Korea
- Eisai
- Iran Telecommunication Research Center
- Servier
- H. Lundbeck A/S
- Ministry of Science and ICT, South Korea
- IXICO
- Chonnam National University Hwasun Hospital
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research
- Institute for Information and Communications Technology Promotion